https://doi.org/10.55788/750fc68a
In patients with advanced ovarian cancer, abdominal retroperitoneal lymphadenectomy must be performed in case of bulky suspicious lymph nodes. In the absence of suspicious bulky lymph nodes, systemic retroperitoneal lymphadenectomy reveals lymph node involvement in almost 50% of cases. Previously, the LION trial (NCT00712218) demonstrated the lack of benefit of adding retroperitoneal lymphadenectomy to primary surgery for advanced epithelial ovarian cancer with clinically negative lymph nodes [1].
The phase 3 CARACO trial (NCT01218490) aimed to evaluate the benefit of systemic retroperitoneal lymphadenectomy at interval surgery after neoadjuvant chemotherapy in patients with advanced ovarian cancer and clinically negative lymph nodes. Prof. Jean-Marc Classe (Nantes Université, France) presented the results [2].
CARACO enrolled 379 participants (FIGO stage III–IVA, clinically lymph node-negative) who were 1:1 randomised to surgery with retroperitoneal lymphadenectomy (RPL arm) or surgery without retroperitoneal lymphadenectomy (no-RPL arm). The median number of resected lymph nodes in the RPL arm was 28. In both arms, approximately 25% of participants underwent primary surgery, and 75% of participants underwent interval surgery after neoadjuvant chemotherapy.
No statistically significant differences were observed in progression-free survival (PFS) and overall survival (OS) between the treatment arms (total population). The median PFS was 14.8 months in the no-RPL arm and 18.6 months in the RPL arm (HR 0.96; P=0.712); median OS was 48.9 versus 58.8 months, respectively (HR 0.92; P=0.489). Likewise, in participants who underwent interval surgery, no statistically significant difference in survival was observed between the no-RPL and RPL arms (PFS: HR 0.89; P=0.374; OS: HR 0.86; P=0.280). Further, RPL was associated with increased severe morbidity (transfusion or blood loss, urinary injury, re-interventions).
“Adding retroperitoneal lymphadenectomy to interval surgery after neoadjuvant chemotherapy in patients with advanced ovarian cancer with clinically negative lymph nodes does not improve survival,” concluded Prof. Classe.
- Harter P, et al. N Engl J Med 2019; 380: 822-832.
- Classe JM, et al. Omission of lymphadenectomy in patients with advanced epithelial ovarian cancer treated with primary or interval cytoreductive surgery after neoadjuvant chemotherapy: The CARACO phase III randomized trial. Abstract LBA5505, ASCO Annual Meeting 2024, 31 May–4 June, Chicago, IL, USA.
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« SIENDO: Efficacy benefit of selinexor in TP53 wildtype endometrial cancer Next Article
Batiraxcept shows promise in high AXL-expressing, platinum-resistant ovarian cancer »
« SIENDO: Efficacy benefit of selinexor in TP53 wildtype endometrial cancer Next Article
Batiraxcept shows promise in high AXL-expressing, platinum-resistant ovarian cancer »
Table of Contents: ASCO 2024
Featured articles
Meet the Trialist: Prof. Giuseppe Curigliano on DESTINY-Breast06
Gastrointestinal: Colorectal Cancer
No survival benefit of tumour debulking for patients with multi-organ metastatic CRC
Thermal ablation of small-size colorectal liver metastases is non-inferior to resection
Benefit of first-line nivolumab/ipilimumab in MSI-H/dMMR metastatic CRC
CodeBreaK 300: Promising survival trends in KRAS G12C-mutated mCRC
Gastrointestinal: Upper GI Cancer
FLOT outperforms CROSS in resectable oesophageal cancer
Nivolumab/ipilimumab combination outperforms TKIs in unresectable HCC
No advantage of neoadjuvant radiochemotherapy over neoadjuvant chemotherapy in borderline resectable pancreatic cancer
Breast Cancer
Benefit of abemaciclib plus fulvestrant after progression on a CDK4/6 inhibitor
ctDNA is prognostic of worse outcomes for CDK4/6 therapy
Adjuvant avelumab significantly improves survival in early TNBC
High pCR rate after neoadjuvant Dato-DXd plus durvalumab therapy
Lung Cancer
Osimertinib significantly improves PFS in patients with unresectable stage III EGFR-mutated NSCLC
First-line lorlatinib provides unprecedented improvement for patients with advanced ALK-positive NSCLC
Comparable benefit of video- and in-person-delivered palliative care
Consolidation with durvalumab improves survival in LS-SCLC
Subcutaneous amivantamab non-inferior and more convenient than intravenous amivantamab
Melanoma
Highly significant event-free survival benefit with neoadjuvant nivolumab/ipilimumab in stage III melanoma
Neoadjuvant intralesional daromun improves relapse-free survival in stage III melanoma
Intratumoural tilsotolimod shows no benefit for advanced refractory melanoma
Genitourinary Cancer
Immune-enhancing nutrition does not affect complication rate of radical cystectomy
ctDNA changes as biomarker for pembrolizumab response in advanced urothelial carcinoma
Highest efficacy of nivolumab/chemotherapy in lymph-node-only metastatic urothelial carcinoma
Genitourinary: Prostate Cancer
Metformin does not prevent progression of low-risk prostate cancer
Baseline ctDNA has both prognostic and predictive value in mCRPC
Oxybutynin significantly decreases frequency and severity of hot flashes in men on ADT
Gynaecological Cancer
Batiraxcept shows promise in high AXL-expressing, platinum-resistant ovarian cancer
No lymphadenectomy for advanced ovarian cancer without suspicious nodes
SIENDO: Efficacy benefit of selinexor in TP53 wildtype endometrial cancer
Novel regimen for HR-positive endometrial cancer on the way?
Related Articles
November 26, 2019
Combination of PARP inhibition plus chemotherapy in ovarian cancer
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com